Salut Brunet

Summary

Affiliation: Hospital de la Santa Creu i Sant Pau
Country: Spain

Publications

  1. ncbi request reprint Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy
    Salut Brunet
    Hematology Department, Hospital de la Sant Creu i Sant Pau, Barcelona, Spain
    Haematologica 89:940-9. 2004
  2. doi request reprint Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience
    José Luis Piñana
    Clinical Hematology and Hematopoietic Transplantation Division, Autonomous University of Barcelona, Barcelona, Spain
    Biol Blood Marrow Transplant 15:21-9. 2009
  3. doi request reprint CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy
    A Perez-Garcia
    Hematology Department, Institut Catalàd Oncologia, Girona, L Hospitalet and Badalona, Spain
    Leukemia 23:486-91. 2009
  4. doi request reprint Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning
    Luca Facchini
    Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Eur J Haematol 88:46-51. 2012
  5. doi request reprint Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing a
    Pere Barba
    Hematology and Stem Cell Transplantation Division Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
    Biol Blood Marrow Transplant 16:413-20. 2010
  6. doi request reprint Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
    Marta Pratcorona
    Hematology Department, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Blood 121:2734-8. 2013
  7. doi request reprint Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation
    Josep Maria Ribera
    Department of Haematology, ICO Hospital Germans Trias i Pujol, Jose Carreras Leukaemia Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain
    Br J Haematol 159:78-81. 2012
  8. doi request reprint Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease
    Irene García-Cadenas
    Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Biol Blood Marrow Transplant 19:435-9. 2013
  9. doi request reprint Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: Final results of a phase 2 study (Burkimab)
    Josep Maria Ribera
    Hematology Department, Institut Català d Oncologia Hospital Germans Trias i Pujol, José Carreras Leukemia Research Institute, Badalona, Spain
    Cancer 119:1660-8. 2013
  10. doi request reprint High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients
    Albert Oriol
    Department of Hematology, ICO Hospital Universitari Germans Trias i Pujol, Badalona Autonomous University, Barcelona, Spain
    Cancer 113:117-25. 2008

Detail Information

Publications62

  1. ncbi request reprint Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy
    Salut Brunet
    Hematology Department, Hospital de la Sant Creu i Sant Pau, Barcelona, Spain
    Haematologica 89:940-9. 2004
    ..To evaluate a regimen of induction and consolidation chemotherapy, followed by a post-remission therapy which depended on age and cytogenetics, in patients with primary acute myeloid leukemia...
  2. doi request reprint Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience
    José Luis Piñana
    Clinical Hematology and Hematopoietic Transplantation Division, Autonomous University of Barcelona, Barcelona, Spain
    Biol Blood Marrow Transplant 15:21-9. 2009
    ..05). ARF is a frequent complication in patients after Allo-RIC, and it has a negative impact on outcome. Identification of ARF risk factors could help to avoid exposure to nephrotoxic drugs during the follow-up in patients at high risk...
  3. doi request reprint CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy
    A Perez-Garcia
    Hematology Department, Institut Catalàd Oncologia, Girona, L Hospitalet and Badalona, Spain
    Leukemia 23:486-91. 2009
    ..64, 95% confidence interval (CI)=1.36-5.14) and lower overall survival at 3 years (39.4 vs 68.4%, P=0.004; HR=2.80, 95% CI=1.39-5.64). This is the first study to report an association between polymorphisms at CTLA-4 and AML relapse...
  4. doi request reprint Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning
    Luca Facchini
    Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Eur J Haematol 88:46-51. 2012
    ..We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100d post-transplant in 195 consecutive adult recipients of a reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC-allo)...
  5. doi request reprint Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing a
    Pere Barba
    Hematology and Stem Cell Transplantation Division Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
    Biol Blood Marrow Transplant 16:413-20. 2010
    ..In conclusion, our single-center study suggests that the flexible HCT-CI is a good predictor of 2-year NRM and survival after an allo-RIC...
  6. doi request reprint Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
    Marta Pratcorona
    Hematology Department, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Blood 121:2734-8. 2013
    ..In conclusion, effect of FLT3 burden is modulated by NPM1 mutation, especially in patients with a low ratio...
  7. doi request reprint Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation
    Josep Maria Ribera
    Department of Haematology, ICO Hospital Germans Trias i Pujol, Jose Carreras Leukaemia Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain
    Br J Haematol 159:78-81. 2012
    ..78%). The reduction in early death, relapse before SCT and transplant-related mortality observed in the ALL-Ph-08 trial resulted in an improved 2-year event-free survival (63% vs. 37%, P = 0·009)...
  8. doi request reprint Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease
    Irene García-Cadenas
    Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Biol Blood Marrow Transplant 19:435-9. 2013
    ..These data highlight the need to investigate new rescue treatments with sustained effect and the importance of reporting long-term outcomes in GVHD studies...
  9. doi request reprint Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: Final results of a phase 2 study (Burkimab)
    Josep Maria Ribera
    Hematology Department, Institut Català d Oncologia Hospital Germans Trias i Pujol, José Carreras Leukemia Research Institute, Badalona, Spain
    Cancer 119:1660-8. 2013
    ..This study prospectively evaluated and compared the outcome and toxicity of human immunodeficiency virus (HIV)-positive and HIV-negative patients with BL who were treated in an intensive immunochemotherapy-based and age-adapted trial...
  10. doi request reprint High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients
    Albert Oriol
    Department of Hematology, ICO Hospital Universitari Germans Trias i Pujol, Badalona Autonomous University, Barcelona, Spain
    Cancer 113:117-25. 2008
    ..The introduction of rituximab in BL therapeutic schemes has been scarcely explored. The outcome and toxicity of HIV-positive patients with BL treated in a rituximab and intensive chemotherapy-based trial was evaluated...
  11. ncbi request reprint High expression of CEACAM6 and CEACAM8 mRNA in acute lymphoblastic leukemias
    Adriana Lasa
    Department of Hematology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Ann Hematol 87:205-11. 2008
    ..It remains to be investigated whether these CEACAM disturbances provide growth advantages to tumoral cells by inhibiting the anoikis process...
  12. doi request reprint Pulmonary function testing prior to reduced intensity conditioning allogeneic stem cell transplantation in an unselected patient cohort predicts posttransplantation pulmonary complications and outcome
    José Luis Piñana
    Hematology and Stem Cell Transplantation Division, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Am J Hematol 87:9-14. 2012
    ..8, 95% CI. 0.98-3.6, P = 0.06 and HR 1.7, 95% CI. 1.1-2.6, P = 0.008). This study emphasizes the valuable role of PFTs in identifying patients at risk for PPC, NRM, and lower OS in the Allo-RIC setting...
  13. ncbi request reprint Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selectio
    Carmen Canals
    Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Exp Hematol 31:1039-43. 2003
    ..The aim of this study was to compare two approaches used to reduce transplant-related mortality (TRM) after allogeneic peripheral blood stem cell transplantation (allo-PBSCT) in elderly patients...
  14. ncbi request reprint Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia
    Mariano Monzo
    Hospital Clinic, Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain
    Blood 107:4871-9. 2006
    ..4; P = .02) and MDR1 (RR = 2.1; P = .02) variant alleles, and WBC count (RR = 2.1; P = .02). These findings might be useful in selecting risk-adapted treatment strategies in intermediate-risk AML...
  15. doi request reprint A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia
    David Valcarcel
    Hematology Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
    Cancer 118:410-7. 2012
    ..A prognostic index to predict induction death in adult patients receiving induction chemotherapy for de novo acute myeloid leukemia (AML) was developed...
  16. ncbi request reprint Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma
    Inigo Espinosa
    Department of Pathology, Hospital de la Santa Creu i Sant Pau, Universidad Autonoma de Barcelona, Barcelona, Spain
    Ann Hematol 85:597-603. 2006
    ..4, P=0.011). Our results suggest that membrane expression of PKC-beta 2 protein on DLBCL predicts for poor survival, especially in patients with low IPI...
  17. ncbi request reprint Microsatellite instability is not an uncommon finding in adult de novo acute myeloid leukemia
    Josep F Nomdedeu
    Department of Hematology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Ann Hematol 84:368-75. 2005
    ..hMLH1 promoter was hypermethylated in five MSI+ cases. Overall survival analysis revealed no adverse effect of MSI positivity. These results suggest that MSI may be a common biologic finding in de novo AML...
  18. ncbi request reprint Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease
    José Luis Piñana
    Division of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Biol Blood Marrow Transplant 12:1135-41. 2006
    ....
  19. ncbi request reprint Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings
    Alvaro Urbano-Ispizua
    Department of Hematology, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Blood 100:724-7. 2002
    ....
  20. doi request reprint Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease
    Montserrat Hoyos
    Spanish CETLAM Group Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona Spanish Cancer Network RTICC, Institut d Investigació Biomèdica Sant Pau, Barcelona, Spain University of Barcelona, Barcelona, Spain
    Eur J Haematol 91:209-18. 2013
    ..In contrast, a minority of them still have a high risk of leukemia recurrence. This study investigated the adverse features of CBF AML that could justify investigational therapeutic approaches...
  21. pmc Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group
    Albert Oriol
    Servei d Hematologia Clinica, Institut Catala d Oncologia, Hospital Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain
    Haematologica 95:589-96. 2010
    ..The objective of this study was to explore the factors influencing the outcome of adult patients with relapsed acute lymphoblastic leukemia...
  22. doi request reprint K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML)
    Maria J Carnicer
    Department of Hematology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Ann Hematol 87:819-27. 2008
    ..K313dup seems to be selected in leukemic cells, and its frequency in other AML series could be determined using the screening method reported in this paper...
  23. doi request reprint Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia
    Blanca Xicoy
    Institut Català d Oncologia Hospital Universitari Germans Trias i Pujol and Institut de Recerca Contra la Leucèmia Josep Carreras, Badalona, Universitat Autonoma de Barcelona, Barcelona, Spain
    Med Clin (Barc) 136:323-8. 2011
    ..This retrospective study aimed to compare the results of CHOP with those from two protocols (PETHEMA-LAL3/97 and BURKIMAB) of specific therapy in Spain...
  24. doi request reprint Epidemiology of aplastic anemia: a prospective multicenter study
    Eva Montané
    Fundacio Institut Catala de Farmacologia, Barcelona, Spain
    Haematologica 93:518-23. 2008
    ..Aplastic anemia is a rare and severe disease. Its incidence varies considerably worldwide. We aimed at describing the epidemiology of this disease, including the incidence, mortality and survival trends, in a well-defined population...
  25. ncbi request reprint Early clinical impact of iron overload in stem cell transplantation. A prospective study
    Albert Altes
    Department of Haematology, Hospital de Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
    Ann Hematol 86:443-7. 2007
    ..In conclusion, iron burden seems to influence the appearance of toxic-infectious complications during the first 3 months after transplant in AUTO-transplanted patients...
  26. ncbi request reprint Acute myeloid leukemia subgroups identified by pathway-restricted gene expression signatures
    Elena Serrano
    Laboratori d Hematologia, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Acta Haematol 116:77-89. 2006
    ..In accordance with previous results, Meis1 downregulation is a useful surrogate marker indicating a good prognosis in AML patients. Simple qPCR platforms may help to identify different biologic subgroups in AML...
  27. ncbi request reprint Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning
    Rodrigo Martino
    Division of Clinical Hematology, Hospital de la Sant Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Biol Blood Marrow Transplant 11:437-47. 2005
    ..In conclusion, therapeutic dose monitoring of oral Bu in a reduced-intensity conditioning setting does not seem to affect outcome, although further studies may identify very-high-risk patients who benefit from this strategy...
  28. ncbi request reprint CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors
    Arianne Perez-Garcia
    Clinical Hematology Department, Alloreactivity Unit, Laborateri de Recerca Translacional, Institut Catala d Oncologia, Hospital Duran i Reynals, Barcelona, Spain
    Blood 110:461-7. 2007
    ..03-2.29). This is the first study to report an association between polymorphisms at CTLA-4 and clinical outcome after allo-HSCT. The CT60 genotype influences relapse and aGVHD, probably due to its action on CTLA-4 alternative splicing...
  29. ncbi request reprint International and Italian prognostic indices in follicular lymphoma
    Granada Perea
    Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Haematologica 88:700-4. 2003
    ..The Italian Lymphoma Intergroup (ILI) created a new prognostic index specific for FL. The aim of this study was to compare which of these two indices is more useful when applied to a large group of FL patients...
  30. doi request reprint A celecoxib derivative inhibits focal adhesion signaling and induces caspase-8-dependent apoptosis in human acute myeloid leukemia cells
    Isolda Casanova
    Networking Research Center on Bioengineering, Biomaterials and Nanomedicine CIBER BBN, Barcelona, Spain
    Int J Cancer 123:217-26. 2008
    ..Finally, our results support the evaluation of celecoxib in AML patients, and the preclinical evaluation of E7123, before its possible clinical testing...
  31. doi request reprint Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate
    Julio Delgado
    Department of Haematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Br J Haematol 145:801-5. 2009
    ..In all survival models, B2M did not attain independent significance unless GFR-B2M was eliminated from the analysis. In conclusion, GFR-B2M is a better predictor of TFS than unadjusted B2M in CLL patients...
  32. ncbi request reprint Bone marrow necrosis with Charcot-Leyden crystals in a patient with idiopathic hypereosinophilic syndrome
    Nuria Pujol-Moix
    Departament d Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Haematologica 88:EIM12. 2003
  33. ncbi request reprint Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients
    Rodrigo Martino
    Division of Clinical Hematology, Hospital de la Sant Creu i Sant Pau, Barcelona, Spain
    Br J Haematol 116:475-82. 2002
    ..Prophylactic strategies for these infections should thus take into account these risk factors...
  34. ncbi request reprint Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors
    Maricel Subirá
    Servei d Hematologia Clinica, Hospital de la Santa Creu i Sant Pau, Av S A M Claret 167, 08025 Barcelona, Spain
    Haematologica 87:528-34. 2002
    ..In this retrospective study we have reviewed all consecutive cases of IPA diagnosed in adult patients with hematologic malignancies in our center from 1995 to 2000 to determine survival and prognostic factors...
  35. ncbi request reprint Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes
    Rodrigo Martino
    Division of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Av Sant Antoni Maria Claret, 167 08025 Barcelona, Spain
    Blood 100:2243-5. 2002
    ..008). These results suggest that a graft-versus-leukemia effect plays a crucial role in reducing the risk of relapse after a RIC allograft in AML and MDS...
  36. doi request reprint Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD)
    Salut Brunet
    Hematology Service, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Curr Opin Oncol 25:195-204. 2013
    ..Optimal postremission therapy for these high-risk molecular cases is not well established; as the prognosis is adverse hematopoietic cell transplantation (HCT), mainly allogeneic HCT (allo-HCT), is the most widely accepted strategy...
  37. ncbi request reprint Hla-DPB1 mismatch in HLA-A-B-DRB1 identical sibling donor stem cell transplantation and acute graft-versus-host disease
    David Gallardo
    Alloreactivity Unit of the Institut Català d Oncologia, Barcelona, Spain
    Transplantation 77:1107-10. 2004
    ..A higher incidence of acute graft-versus-host disease (aGVHD) has been described after unrelated donor bone marrow transplant when both HLA-DPB1 alleles were mismatched...
  38. ncbi request reprint Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study
    Albert Oriol
    Servei d Hematologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    Haematologica 88:445-53. 2003
    ..A protocol was designed to treat all adult patients with mature B-cell lymphoma or leukemia with the aims of comparing the response to therapy and survival with regards to their HIV infection status...
  39. ncbi request reprint Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation
    Federico Moscardo
    Hematology Department, Hospital Universitario La Fe, Avda Campanar 21, 46009 Valencia, Spain
    Exp Hematol 31:545-50. 2003
    ..However, no comparative studies have been performed to investigate this. We analyzed the influence of selection for CD34(+) cells on the incidence and severity of hepatic veno-occlusive disease (VOD)...
  40. ncbi request reprint CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections
    Albert Altes
    Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
    Exp Hematol 30:824-30. 2002
    ..The main objective of this work was to decrease the incidence of relapse after autologous stem cell transplantation with a "double purging" procedure...
  41. pmc Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis
    Pau Montesinos
    Hematology Department, Hospital Universitario La Fe, Avda Campanar 21, Valencia, Spain
    Haematologica 94:1242-9. 2009
    ..The prevalence of and risk factors for central nervous system recurrence in patients with acute promyelocytic leukemia are not well established and remain a controversial matter...
  42. ncbi request reprint Second mobilization and collection of peripheral blood progenitor cells in healthy donors is associated with lower CD34(+) cell yields
    Javier de la Rubia
    Spanish Group of Allogeneic Peripheral Blood Stem Cell Transplantation, La Fe University Hospital, 4600 Valencia, Spain
    J Hematother Stem Cell Res 11:705-9. 2002
    ..057). Our study shows that second rounds of PBPC collection from normal donors are well tolerated but are associated with a significantly reduced number of CD34(+) cells collected when the same mobilization scheme is used...
  43. ncbi request reprint Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: a prospective assessment
    Raymond Miralbell
    University Hospital of Geneva, Geneva, Switzerland
    Int J Radiat Oncol Biol Phys 58:809-16. 2004
    ..A study was undertaken to assess prospectively the subclinical renal function changes with radioisotopic methods in patients undergoing BMT for hematologic malignancies...
  44. ncbi request reprint Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia
    Albert Oriol
    Haematologica 88:229-30. 2003
  45. ncbi request reprint Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation
    Johannes Schetelig
    Klinik für Innere Medizin m S Hämatologie und Onkologie, Humboldt Universitat, Germany
    Haematologica 88:1272-8. 2003
    ..Patients with angioimmunoblastic T-cell lymphoma (AIL) have a poor prognosis with conventional treatment...
  46. ncbi request reprint Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors
    Javier de la Rubia
    Hematology Service, Hospital La Fe, Valencia, Spain
    Transfusion 42:4-9. 2002
    ..Predictive factors of the response to rHuG-CSF in normal donors have not been extensively studied...
  47. ncbi request reprint Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation
    Jose A Perez-Simon
    Department of Hematology, Hospital Clinico Universitario, Salamanca, Spain
    Blood 102:1108-13. 2003
    ....
  48. ncbi request reprint Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation
    Luis Villela
    Servei d Hematologia Clinica, Hospital de la Santa Creu i Sant Pau, Antoni Maria i Claret 167, 08025 Barcelona, Spain
    Haematologica 88:300-5. 2003
    ..We evaluated the results of ASCT in a group of 49 patients >= 60 years of age [32 males, median age 63 years (range, 60 to 71)] autografted in our institution from January 1995 to December 2001...
  49. ncbi request reprint Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation
    Miguel A Diaz
    Spanish Group for Allogeneic Peripheral Blood Stem Cell Transplantation
    Haematologica 88:919-22. 2003
    ..In this study we analyzed predictive factors for PBPC collection in pediatric donors...
  50. ncbi request reprint Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation
    Jose A Perez-Simon
    Servicio de Hematlogía, Hospital Clinico Universitario, Salamanca, Spain
    Br J Haematol 130:394-403. 2005
    ....
  51. ncbi request reprint Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia
    Juan Manuel Sancho
    Clinical Hematology Department, Institut Català d Oncologia Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Eur J Haematol 78:102-10. 2007
    ..We present the results of treatment of Philadelphia chromosome-negative (Ph-) ALL patients over 55 yr treated in the PETHEMA ALL-96 trial...
  52. ncbi request reprint Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study
    Albert Oriol
    Haematologica 90:990-2. 2005
    ..051). We extended the follow-up analysis to elucidate the role of HAART in the survival of HIV-infected patients included in the PETHEMA-LAL3/97 protocol...
  53. ncbi request reprint Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia
    Pascual Bolufer
    Laboratory of Molecular Biology Medical Biopathology, Hospital Universitario La Fe, Valencia, Spain
    Br J Haematol 136:590-6. 2007
    ..42, 95% CI = 1.59-212.76, P = 0.02 respectively). Thus, the profiles of genetic polymorphisms of drug-metabolising enzymes might explain the increased risk to t-AML/t-MDS observed in some patients treated with polychemotherapy...
  54. ncbi request reprint Post-transplant Burkitt's leukemia or lymphoma. Study of five cases treated with specific intensive therapy (PETHEMA ALL-3/97 trial)
    Blanca Xicoy
    Services of Hematology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Leuk Lymphoma 44:1541-3. 2003
    ..Two patients died in induction, another died in consolidation phase and the remaining 2 patients are in continuous complete remission 6 and 18 months from the diagnosis...
  55. ncbi request reprint Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease
    Manuel Jurado
    Department of Hematology, Hospital Virgen de las Nieves, Granada, Spain
    Biol Blood Marrow Transplant 13:701-6. 2007
    ..Further investigation is warranted to elucidate the role of sirolimus in cGVHD, and find the best combination (sirolimus + calcineurin inhibitors versus others) for therapeutic use...
  56. doi request reprint Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
    Javier de la Serna
    Hospital 12 de Octubre, Madrid, Spain
    Blood 111:3395-402. 2008
    ..These data furnish clinically relevant information that might be useful for designing more appropriately risk-adapted treatment protocols aimed at reducing the considerable problem of induction mortality in APL...
  57. ncbi request reprint Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia
    Silvia Casas
    Department of Hematology, Hospital Sant Pau Autonomous University of Barcelona, Avda Sant Antoni Ma Claret 167, Barcelona 08025, Spain
    Cancer Genet Cytogenet 153:16-25. 2004
    ..Application of the CGH technique is thus a useful complementary diagnostic tool for CCA in de novo AML cases with abnormal karyotypes or with unsuccessful cytogenetics...
  58. doi request reprint Uniparental disomy may be associated with microsatellite instability in acute myeloid leukemia (AML) with a normal karyotype
    Elena Serrano
    Department of Haematology, Hospital de Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain
    Leuk Lymphoma 49:1178-83. 2008
    ..MSI involved the polymorphic PIG3 promoter in two UPD+ cases. It remains to be tested whether UPD and MSI association marks a common pathway of leukemogenesis...
  59. ncbi request reprint Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol
    Albert Oriol
    CETLAM Group, Catalonia, Spain
    Haematologica 89:791-800. 2004
    ..We assessed the proportion of patients over 60 years with de novo AML who qualified for intensive therapy and determined the feasibility and results of autologous stem cell transplantation (ASCT) in first complete remission (CR)...
  60. ncbi request reprint FLT3 mutations are associated with other molecular lesions in AML
    Maria J Carnicer
    Laboratori d Hematologia, Hospital de la Santa Creu i Sant Pau, Avda Sant Antoni M Claret, 167, 08025 Barcelona, Spain
    Leuk Res 28:19-23. 2004
    ..4% of patients showed Class I + Class II mutations. Our findings could be consistent with the cooperative model. The search for new tyrosine kinases which can be the target of molecular lesions in AML warrants further investigation...
  61. doi request reprint Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias
    Elena Serrano
    Department of Hematology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain
    Leuk Res 32:944-53. 2008
    ..Furthermore, some of the genes deregulated by the leukemogenic process reverted to their normal expression with demethylating and HDAC inhibitor treatment, highlighting the role of chromatin remodeling processes in AML...
  62. doi request reprint Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
    Miguel A Sanz
    Hospital Universitario La Fe, Valencia, Spain
    Blood 112:3130-4. 2008
    ..04, respectively). This updated analysis confirms the high antileukemic efficacy, low toxicity, and high degree of compliance of a risk-adapted strategy combining ATRA and anthracycline monochemotherapy for consolidation therapy...